Arvinas, Pfizer announce initial phase 1b data from the TACTIVE-U …
Dec 12, 2024 · Arvinas, Pfizer announce initial phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combo with abemaciclib at 2024 SABC symposium
Rusan Pharma achieves dual GMP milestones from TGA, Australia …
Dec 13, 2024 · Rusan Pharma achieves dual GMP milestones from TGA, Australia and ANVISA, for its manufacturing facility: Our Bureau, Mumbai Friday, December 13, 2024, 16:45 Hrs [IST]
US FDA accepts GSK’s submission for the use of Nucala to treat …
Dec 11, 2024 · GSK plc announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the regulatory review process to obtain a new indication for the use of Nucala (mepolizumab), as an add-on maintenance treatment for patients with chronic obstructive pulmonary ...
FDI equity inflow into pharma sector grows to $520 million in …
Dec 11, 2024 · FDI equity inflow into pharma sector grows to $520 million in H1FY25: Gireesh Babu, New Delhi Wednesday, December 11, 2024, 08:00 Hrs [IST] The Foreign Direct Investment (FDI) equity inflow into the pharmaceutical sector has reported multifold growth during the first half of 2024-25, after registering a 48 per cent decline in …
Clariant introduces new high-performing excipients at the CPHI …
Nov 25, 2024 · Clariant introduces new high-performing excipients at the CPHI India 2024 trade show: Our Bureau, Mumbai Monday, November 25, 2024, 16:15 Hrs [IST]
Aptamer developed by HKBU for treating rare bone disease ‘X …
Dec 26, 2024 · Aptamer developed by HKBU for treating rare bone disease ‘X-linked hypophosphatemia’ receives orphan drug designation & rare paediatric disease designation from US FDA
Merck reports positive results from pivotal phase 3 trials of once ...
Dec 23, 2024 · Merck reports positive results from pivotal phase 3 trials of once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir to treat patients with virologically suppressed HIV-1 infection
Daiichi Sankyo’s Datroway gets Japanese regulatory nod for first …
Dec 28, 2024 · Daiichi Sankyo’s Datroway gets Japanese regulatory nod for first TROP-2 directed therapy for previously treated unresectable or recurrent HR positive, HER2 negative breast cancer
IGI presents first clinical data from phase 1 study of trispecific ...
Dec 10, 2024 · IGI presents first clinical data from phase 1 study of trispecific TREAT antibody demonstrates high overall response rate: Our Bureau, Mumbai Tuesday, December 10, 2024, 16:10 Hrs [IST]
NIH study finds tecovirimat was safe but did not improve mpox ...
Dec 12, 2024 · NIH study finds tecovirimat was safe but did not improve mpox resolution or pain: Bethesda, Maryland Thursday, December 12, 2024, 15:00 Hrs [IST]